Brenntag’s Restructuring Push Meets a Market That No Longer Cooperates
19.06.2026 - 18:24:25 | boerse-global.de
The tailwind that had lifted Brenntag’s shares through March has vanished. A US-Iran framework agreement to de-escalate the Gulf conflict and gradually reopen the Strait of Hormuz – a chokepoint for roughly a fifth of global oil and LNG trade – has reversed the pricing dynamics that briefly buoyed the entire European chemical sector.
For Brenntag, the first quarter of 2026 had brought a short-term geopolitical boost. The company capitalised on disrupted supply chains and its own pricing discipline to ride a wave of fear-driven demand. Now that the strait is reopening and oil prices are falling, that advantage has evaporated. Chemical buyers are no longer scrambling for inventory; they are destocking. The result is a brutal return to price competition.
Fundamentals reflect the pressure
Brenntag’s first-quarter numbers lay bare the strain. Revenue came in at €3.7bn, a decline of 5.1% from the prior year. Operating EBITDA fell 8.3% to €306m. The pattern matches the broader industry: Germany’s chemical industry association reported seasonally adjusted production down 2.8% in the first quarter, and the Stoxx Europe 600 Chemicals index has shed significant ground.
There is, however, one bright spot. Gross margin improved to 25.9%, up 0.9 percentage points year-on-year, driven by an ongoing cost-cutting programme that delivered €27m in savings during the quarter. The company still aims for total savings of €200m to €250m by 2027.
Should investors sell immediately? Or is it worth buying Brenntag?
A structural shift in business model
Underlying the margin pressure is a more fundamental change. For years, strong demand and broken supply chains gave Brenntag pricing power that fuelled record profits. Those days are over. Supply routes are functioning again, industrial customers are working down bloated inventories, and the distributor is being forced into price battles on basic chemicals.
Management is responding by splitting the business into two separate divisions: Essentials and Specialties. The goal is to sharpen efficiency and insulate the higher-margin specialties arm from the commoditised price war in base chemicals. Whether the reorganisation is already paying off will become clearer when second-quarter results are released in August.
Technical support under scrutiny
Brenntag’s stock has not escaped the selling pressure. At around €54.04, the shares trade nearly 15% below the 52-week high of €63.76 set in mid-April. Over the past month, the decline has been roughly 8.5%, pushing the price below the 100-day moving average of €55.73. The relative strength index now stands at 34.6, close to the oversold threshold.
The next line of defence is the 200-day moving average at €52.65. As long as that holds, the longer-term uptrend remains intact. A break below that level would open the door to the €50 area.
Brenntag at a turning point? This analysis reveals what investors need to know now.
What lies ahead
Brenntag is sticking with its full-year guidance of operating EBITDA between €1.15bn and €1.35bn. The cost programme is the primary lever for cushioning what remains a weak industrial economy in Europe and North America.
Investors will get a full strategic update at a Capital Markets Day scheduled for 12 November 2026. Until then, the market’s focus will be on whether the restructuring can offset a structural shift that has stripped the company of the pricing power it once enjoyed.
Ad
Brenntag Stock: New Analysis - 19 June
Fresh Brenntag information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
